Phaseline

Companies › Glaukos

Glaukos: clinical trials, targets and expected readouts

5 active drug programs in 9 registered trials: 4 Phase 4, 4 Phase 2, 1 Phase 3; Ophthalmology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Travoprost
Prostanoid FP receptor agonist
PTGFRPhase 4Glaucoma, Open-Angle; Glaucoma, Open-angle; Glaucoma; Open Angle GlaucomaMay 2027
Riboflavin Ophthalmic Solutions
Photosensitizer used in corneal cross-linking
–Phase 4KeratoconusSep 2027
GLK-321–Phase 2Demodex BlepharitisNov 2026
GLK-221 Ophthalmic Solution–Phase 2KeratoconusApr 2027
lufepirsen
connexin43 antisense oligonucleotide
GJA1Phase 2Persistent Corneal Epithelial Defect–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05966493lufepirsenPhase 2Persistent Corneal Epithelial DefectOphthalmologyDec 2025
NCT07400965GLK-321Phase 2Demodex BlepharitisOphthalmologyNov 2026
NCT07400952GLK-221 Ophthalmic SolutionPhase 2KeratoconusOphthalmologyApr 2027
NCT06066645TravoprostPhase 4Glaucoma, Open-AngleOphthalmologyMay 2027
NCT06848946TravoprostPhase 4Glaucoma, Open-angleOphthalmologyJun 2027
NCT07629557Riboflavin Ophthalmic SolutionsPhase 4KeratoconusOphthalmologySep 2027
NCT07075718TravoprostPhase 2GlaucomaOphthalmologyMar 2028
NCT07495852TravoprostPhase 3GlaucomaOphthalmologyJun 2028
NCT07228221TravoprostPhase 4Open Angle GlaucomaOphthalmologyAug 2031

From the company's SEC filings

Cash of $162m on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

PTGFR (1) GJA1 (1)

Companies with the same targets

SpyGlass Pharma YS Life Science Santen Pharmaceutical Triple Hair

Companies built like this

YS Life Science Bausch & Lomb Santen Pharmaceutical Laboratoires Thea Taejoon Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.